Intraoperative Placement of Superficial Erector Spinae Plane Block; A New Approach in Spine Surgery

NCT ID: NCT05244031

Last Updated: 2022-03-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

46 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-05-10

Study Completion Date

2022-02-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Major spine surgery causes severe postoperative pain. The primary objective of this randomized controlled study is to compare the effect of ultrasound (US)-guided superficial erector spinae plane (ESP) block on 48-hour postoperative cumulative opioid requirements with standard (opioid-based) analgesia.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

46 patients (ASA I-II-III) between 18 and 65 years of age, who were to undergo spine surgery, were randomized and divided into two groups. (23 patients in each of the control and superficial ESP groups). Superficial ESP block was performed for SESP group and standard (opioid-based) analgesia performed in the control group. Postoperative analgesia was provided by intravenous morphine infusion using a patient-controlled analgesia device. Postoperative numeric rating scale values were the primary outcome measure. 24-hour total morphine consumption was secondary outcome measure.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Postoperative Pain Spine Deformity Spine Injury Spine Fracture Spine Malformation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Superficial ESP

The investigators performed superficial erector spina plane block to that patient group for postoperative analgesia

Group Type ACTIVE_COMPARATOR

superficial erector spina plane block

Intervention Type PROCEDURE

The investigators performed superficial erector spina plane block to that patient group for postoperative analgesia

Control group

The investigators performed intravenous opioid infusion with PCA to that patient group for postoperative analgesia

Group Type ACTIVE_COMPARATOR

Standard (opioid-based) analgesia

Intervention Type PROCEDURE

The investigators performed intravenous opioid infusion with PCA to that patient group for postoperative analgesia

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

superficial erector spina plane block

The investigators performed superficial erector spina plane block to that patient group for postoperative analgesia

Intervention Type PROCEDURE

Standard (opioid-based) analgesia

The investigators performed intravenous opioid infusion with PCA to that patient group for postoperative analgesia

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Ages of 18-65
* Patients who will undergo spine surgery (at least two level)
* ASA I-II-III patients

Exclusion Criteria

* Clinically known local anesthetic allergy
* Morbid obesity (body mass index\>40 kg m2)
* Clinically diagnosis of opioid, alcohol and substance dependence
* Clinically diagnosis of psychiatric disease
* Coagulopathy
* Patients with ASA IV-V
* Single level surgery
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Bakirkoy Dr. Sadi Konuk Research and Training Hospital

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Gokhan Sertcakacilar, MD

Principal investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Bakirkoy Dr. Sadi Konuk Research and Training Hospital

Istanbul, Bakirkoy, Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2021-271

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.